

Appendix 4D

Financial statements for the half-year ended 31 December 2023

as required by ASX listing rule 4.2A

1. Company details

Name of entity:	Clarity Pharmaceuticals Ltd
ABN:	36 143 005 341
Reporting period:	Half Year ended 31 December 2023
Previous period:	Half Year ended 31 December 2022

2. Results for announcement to the market

				\$'000
Revenue from ordinary activities	up	0%	to	0
Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd	up	53%	to	(17,203)
Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd	up	53%	to	(17,203)

Dividends

There were no dividends paid, recommended, or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$17,202,718.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2023.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	20.2	31.5

4. Control gained over entities

Not applicable

5. Loss of control over entities

Not applicable.

Appendix 4D

Financial statements for the half-year ended 31 December 2023

as required by ASX listing rule 4.2A

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

This report is based on the consolidated financial statements for the half-year ended 31 December 2023. The half-year financial statements have been reviewed by Grant Thornton Audit Pty Limited who have issued an unmodified review conclusion with a material uncertainty related to going concern. The company has addressed this matter in Note 1 to the financial statements.

In the preparation of the Half Year financial statements ended 31 December, management identified an understatement in the calculation of share-based payments expense in prior periods. The understatement has been quantified and is considered immaterial both in respect of current and prior periods. Management will however update the comparative disclosures pertaining to Key Management Personnel (KMP) in the Remuneration Report for 30 June 2024.

8. Attachments

Details of attachments (if any):

The Half Year Financial Statements of Clarity Pharmaceuticals Ltd for the period ended 31 December 2023 are attached.

9. Signed

As authorised by the Board of Directors



Robert Vickery
Company Secretary
29 February 2024